| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antiatherogenic properties of metformin: the experimental evidence
|
Mamputu, J.C.
|
|
2003
|
|
4P2 |
p. 6S71-6S76
nvt p.
|
artikel
|
| 2 |
Beneficial effects of metformin on haemostasis and vascular function in man
|
Grant, P.J.
|
|
2003
|
|
4P2 |
p. 6S44-6S52
nvt p.
|
artikel
|
| 3 |
Changing practices in insulin therapy in France
|
Slama, G.
|
|
2005
|
|
4P2 |
p. 4S5-4S6
nvt p.
|
artikel
|
| 4 |
Do effects on blood pressure contribute to improved clinical outcomes with metformin?
|
Schäfers, R.F.
|
|
2003
|
|
4P2 |
p. 6S62-6S70
nvt p.
|
artikel
|
| 5 |
How to achieve a predictable basal insulin?
|
Kurtzhals, P.
|
|
2005
|
|
4P2 |
p. 4S25-4S33
nvt p.
|
artikel
|
| 6 |
Improving survival with metformin: the evidence base today
|
Scarpello, J.H.B.
|
|
2003
|
|
4P2 |
p. 6S36-6S43
nvt p.
|
artikel
|
| 7 |
Intensive insulin therapy today: ‘basal-bolus’ using multiple daily injections or CSII?
|
Renard, E.
|
|
2005
|
|
4P2 |
p. 4S40-4S44
nvt p.
|
artikel
|
| 8 |
Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
|
Valensi, P.
|
|
2005
|
|
4P2 |
p. 4S34-4S39
nvt p.
|
artikel
|
| 9 |
Is metformin more than an oral hypoglycaemic agent?
|
Vague, P.
|
|
2003
|
|
4P2 |
p. 6S5-6S7
nvt p.
|
artikel
|
| 10 |
Limitations of the so-called “intensified” insulin therapy in type 1 diabetes mellitus
|
Jacqueminet, S.
|
|
2005
|
|
4P2 |
p. 4S45-4S50
nvt p.
|
artikel
|
| 11 |
Metformin and vascular protection: a cardiologist's view
|
Libby, P.
|
|
2003
|
|
4P2 |
p. 6S117-6S120
nvt p.
|
artikel
|
| 12 |
Metformin and vascular protection: a diabetologist's view
|
Garber, A.J.
|
|
2003
|
|
4P2 |
p. 6S113-6S116
nvt p.
|
artikel
|
| 13 |
Metformin: drug of choice for the prevention of type 2 diabetes and cardiovascular complications in high-risk subjects
|
Standl, E.
|
|
2003
|
|
4P2 |
p. 6S121-6S122
nvt p.
|
artikel
|
| 14 |
Metformin inhibition of glycation processes
|
Beisswenger, P.
|
|
2003
|
|
4P2 |
p. 6S95-6S103
nvt p.
|
artikel
|
| 15 |
Microcirculation in insulin resistance and diabetes: more than just a complication
|
Wiernsperger, N.F.
|
|
2003
|
|
4P2 |
p. 6S77-6S87
nvt p.
|
artikel
|
| 16 |
Mitochondrial metabolism and type-2 diabetes: a specific target of metformin
|
Leverve, X.M.
|
|
2003
|
|
4P2 |
p. 6S88-6S94
nvt p.
|
artikel
|
| 17 |
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes
|
Després, J.P.
|
|
2003
|
|
4P2 |
p. 6S53-6S61
nvt p.
|
artikel
|
| 18 |
Reducing insulin resistance with metformin: the evidence today
|
Giannarelli, R.
|
|
2003
|
|
4P2 |
p. 6S28-6S35
nvt p.
|
artikel
|
| 19 |
Subcutaneous insulin: pharmacokinetic variability and glycemic variability
|
Guerci, B.
|
|
2005
|
|
4P2 |
p. 4S7-4S24
nvt p.
|
artikel
|
| 20 |
The burden of type 2 diabetes: are we doing enough?
|
Zimmet, P.
|
|
2003
|
|
4P2 |
p. 6S9-6S18
nvt p.
|
artikel
|
| 21 |
The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications
|
Eschwège, E.
|
|
2003
|
|
4P2 |
p. 6S19-6S27
nvt p.
|
artikel
|
| 22 |
The potential of metformin for diabetes prevention
|
Slama, G.
|
|
2003
|
|
4P2 |
p. 6S104-6S111
nvt p.
|
artikel
|
| 23 |
Weight gain and insulin treatment
|
Larger, E.
|
|
2005
|
|
4P2 |
p. 4S51-4S56
nvt p.
|
artikel
|
Tijdschrift beschrijving